

# Suzanne Carreira

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4826536/publications.pdf>

Version: 2024-02-01

37  
papers

6,980  
citations

279798

23  
h-index

377865

34  
g-index

37  
all docs

37  
docs citations

37  
times ranked

9176  
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	27.0	1,796
2	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 443-453.	27.0	1,205
3	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11428-11436.	7.1	839
4	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 162-174.	10.7	450
5	Plasma <i>AR</i> and abiraterone-resistant prostate cancer. <i>Science Translational Medicine</i> , 2015, 7, 312re10.	12.4	366
6	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , 2017, 7, 1006-1017.	9.4	341
7	Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. <i>European Urology</i> , 2019, 76, 469-478.	1.9	269
8	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 192-208.	8.2	266
9	Genomics of lethal prostate cancer at diagnosis and castration resistance. <i>Journal of Clinical Investigation</i> , 2020, 130, 1743-1751.	8.2	180
10	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 4441-4453.	8.2	155
11	Targeting the p300/CBP Axis in Lethal Prostate Cancer. <i>Cancer Discovery</i> , 2021, 11, 1118-1137.	9.4	124
12	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). <i>Clinical Cancer Research</i> , 2018, 24, 3149-3162.	7.0	111
13	Detection of circulating tumour cell clusters in human glioblastoma. <i>British Journal of Cancer</i> , 2018, 119, 487-491.	6.4	98
14	Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. <i>Clinical Cancer Research</i> , 2018, 24, 5635-5644.	7.0	88
15	Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. <i>Cancer Research</i> , 2016, 76, 2731-2742.	0.9	79
16	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. <i>Cancer Discovery</i> , 2021, 11, 2812-2827.	9.4	78
17	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , 2021, 79, 200-211.	1.9	76
18	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. <i>European Urology</i> , 2019, 75, 184-192.	1.9	69

#	ARTICLE	IF	CITATIONS
19	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 676-685.	1.9	62
20	Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1965-1976.	7.0	55
21	Characterizing CDK12-Mutated Prostate Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 566-574.	7.0	50
22	The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 3987-4005.	8.2	37
23	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. <i>Clinical Cancer Research</i> , 2017, 23, 6070-6077.	7.0	30
24	Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. <i>European Urology</i> , 2021, 80, 243-253.	1.9	28
25	HER3 Is an Actionable Target in Advanced Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 6207-6218.	0.9	25
26	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. <i>Cancer Research</i> , 2022, 81, 1087-1100.	0.9	23
27	Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	19
28	Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. , 2022, 10, e004495.		14
29	Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3104-3115.	7.0	12
30	Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. , 2020, 8, e000713.		8
31	Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2022, 5, 659-667.	5.4	8
32	HER3 expression and MEK activation in non-small-cell lung carcinoma. <i>Lung Cancer Management</i> , 2021, 10, LMT48.	1.5	7
33	Targeting radioresistance and replication fork stability in prostate cancer. <i>JCI Insight</i> , 2022, 7, .	5.0	4
34	Elucidating Durable Responses to Immune Checkpoint Inhibition. <i>European Urology</i> , 2020, 78, 639-641.	1.9	3
35	Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1020-1029.	4.1	3
36	Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100309.	1.7	2

#	ARTICLE	IF	CITATIONS
37	Preliminary evidence of antitumour activity of Ipatasertib (Ipat) and Atezolizumab (ATZ) in glioblastoma patients (pts) with PTEN loss from the Phase 1 Ice-CAP trial (NCT03673787). Neuro-Oncology, 2021, 23, iv10-iv10.	1.2	0